Compare Carvana Co (CVNA) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Cassava Sciences Inc — how do they compare? Carvana Co trades at $64.26 (market cap $69.55B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Carvana Co is far larger — about 1765.2× Cassava Sciences Inc's market cap, and Carvana Co is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Cassava Sciences Inc for 37 Days on average.
| CVNA | FLNA | |
|---|---|---|
Market Cap | $69.55B | $39.40M |
Volume | 7,671,750 | 759,018 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $4.64 |
52-Week Low | $56.27 | $0.68 |
Typical Hold Time | 28 Days | 37 Days |
Enterprise Value | $72.04B | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $62.76, down 1.72% with bearish technical signals but strong fundamental momentum. The stock shows impressive revenue growth from $13.7B in 2024 to $20.3B in 2025, with net income surging to $1.4B. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.42 exceeding the $0.39 forecast. Analyst sentiment remains divided with a $84.07 consensus target, though technical indicators show selling pressure with bearish moving averages and key resistance at $64.
Carvana presents a compelling growth story with expanding profitability and operational efficiency, though high valuation multiples and significant debt levels warrant caution. The company's aggressive capacity expansion addresses demand constraints, positioning it for continued market share gains in online auto retail. However, competitive pressures and macroeconomic sensitivity to interest rates remain key risks for investors.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
